4/3
10:46 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
4/3
10:46 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
4/3
10:24 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
4/3
10:24 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
4/3
08:04 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
4/3
08:03 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
4/3
05:38 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
4/3
05:38 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
3/11
02:56 pm
arqt
Rating for ARQT
Low
Report
Rating for ARQT
3/11
02:56 pm
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/27
11:38 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/27
11:38 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/27
11:38 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/26
12:28 pm
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
2/26
11:07 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/26
11:07 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/26
08:00 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
2/26
06:18 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/26
06:18 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/24
10:19 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/24
10:19 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/24
10:15 am
arqt
Rating for ARQT
Medium
Report
Rating for ARQT
2/24
10:15 am
arqt
Rating for ARQT
Medium
Report
Rating for ARQT
2/10
09:45 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/10
09:45 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Guggenheim.